12:00 AM
 | 
Feb 25, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

NanoString sales and marketing update

NanoString launched Prosigna Breast Cancer Prognostic Gene Signature Assay in the EU and Israel to subtype breast cancer tumor and estimate the probability of cancer...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >